Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease
复制标题
两种不同剂量的米诺环素与安慰剂治疗轻度阿尔茨海默病患者的比较
作者：
R. Howard;O. Zubko;R. Bradley;Emma Harper;Lynn Pank;J. O'Brien;C. Fox;N. Tabet;G. Livingston;P. Bentham;R. McShane;A. Burns;C. Ritchie;S. Reeves;S. Lovestone;C. Ballard;W. Noble;R. Nilforooshan;G. Wilcock;R. Gray
2年米诺环素治疗能否改变轻度阿尔茨海默病的病程？结果在这项随机临床试验中，包括544名参与者，24个月的米诺环素治疗没有显着延迟功能和认知障碍的进展相比，安慰剂。这意味着米诺环素不是症状性阿尔茨海默病患者疾病改善的候选药物。
Key Points Question Can 2 years of minocycline treatment modify the course of mild Alzheimer disease? Findings In this randomized clinical trial that included 544 participants, 24 months of minocycline treatment did not significantly delay progression of functional and cognitive impairment compared with placebo. Meaning Minocycline is not a candidate for disease modification for patients with symptomatic Alzheimer disease.
米诺环素神经保护的前景。
影响因子：
--
作者：
Plane, Jennifer M.;Shen, Yan;Pleasure, David E.;Deng, Wenbin
通讯作者：
Deng, Wenbin